RE:RE:RE:RE:RE:RE:RE:Forget news speculation; Mackie's report catapulted price!forget your asumptions guys, the FDA approval and Ph2 results will bring us into next level and into buyout at yr 2020, accumulate as much as you can...
Longholder99 wrote: The Mackie report suggests to me that .80 is the bare minimum we can expect to see without any speculative SP advancement from good Ph2 results whixh we dont have yet, and other events they are not mathematically able to calculate value upon based on the current state of the company. Once the FDA approval and or Ph2 results start coming in these events will then be non speculative and part of the Mackie equation bringing their estimate up dramatically based on proposed NMIBC market share etc. Am I off here?
How many times ...
2014 sales pitch.. buy TLT at .30 get in this great opportunity. Private research IPO at $3 bucks..
Low float, no debt
Finishing Pre-Rats
Top Doctors
yada yada
2019 sales pitch buy TLT at .30 we're treating humans now
Have a fully funded ORF 4.5 m fund paying for the completion of preclin on 5 indications
US FDA very close
In 3 centres and have found 3 more in the onboarding process.
Ya... i think .80 is severly undervalued.
$3 isn't even bullish...... once you adjust for the opportunity cost and dilution......
these phase 2 results at 90 days just goes to fulfill the 2014 sales pitch and confirm what Theralase would of IPO'd at with a Nasdaq Listing
A listing years in the promising.
Sigh... 5 years of derisking... and you guys jizz to very very minor green days
[/quote]